Trigeminal neuralgia (TN), also known as tic douloureux, is a chronic pain disorder that affects the fifth cranial or trigeminal nerve. It causes inflammatory conditions due to systemic diseases including Lyme disease, sarcoidosis, and multiple sclerosis. There is also an association with collagen vascular diseases including systemic lupus erythematosus and scleroderma. The condition is treated on an outpatient basis, except till neurosurgical intervention is required. Its management must be customized individually, based on the patient's general condition and age. However, the exact cause of the condition is unknown.

Trigeminal neuralgia treatment market can be subdivided into drug therapy and surgery. Trigeminal neuralgia surgery is undertaken if medication causes troublesome side-effects or does not work. There are three main types of surgeries, rhizotomy, stereotactic radiosurgery and microvascular decompression. Rhizotomy is an outpatient procedure performed under general anesthesia. It involves destroying the fibers within the trigeminal nerve that are carrying pain signals. Microvascular decompression is the most curative and permanent surgery for trigeminal neuralgia treatment. It is usually offered to patients who are not too older and are in reasonably good health.

Idiopathic trigeminal neuralgia, for which cause is unknown, is mostly treated with a single anticonvulsant medication such as carbamazepine. Carbamazepine, oxcarbazepine, gabapentin, lamotrigine or baclofen are some drugs used in treatment of TN. Carbamazepine often works well for trigeminal neuralgia and can ease symptoms of TN within 1-2 days. Its dose varies from patient to patient. Other medicines that ease nerve impulses can be used in combination of two drugs if one alone does not help. However, these medicines can cause various side effects such as amnesia, nausea, drowsiness, dizziness, and unsteadiness. Moreover, these drugs lose their effectiveness with time, requiring greater number of medications or higher doses taken together. Some patients experience side effects serious enough to discontinue the medication. Furthermore, some issues about diagnosis, surgical and pharmacological treatment of TN are unsettled. Major issues to address in the management of patients with TN include persistent side effects from medication, continued delays in diagnosis, and a lack of psychological support. All these factors are expected to hinder growth of the market during the forecast period. However, the European Federation of Neurological Societies and the American Academy of Neurology launched a combined task force to prepare general guidelines for the management of trigeminal neuralgia.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/1536

Market Dynamics

Increasing number of geriatric population is expected to drive growth of the trigeminal neuralgia treatment market worldwide as elderly people are more prone to get affected. Trigeminal neuralgia majorly affects people with age of 50 or more. It can occur at any age, including infancy. Young adults suffering from multiple sclerosis have high risk of developing TN. According to national Institute of Neurological Disorders and Stroke (NINDS), the number of new cases is around 12 per 100,000 each year. The condition is more common among women than in men. In young individuals, the cause is mostly idiopathic, but as compared to elderly, adult cases are mostly caused due to central nervous system damage similar to individuals with multiple sclerosis. The condition is extremely rare in children. However, various side effects such as amnesia, nausea, drowsiness, dizziness, and unsteadiness caused due to medications can negatively impact growth of the market. Furthermore, these drugs lose their efficacy over time.

Regional Insights

Regional segmentation of trigeminal neuralgia market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America trigeminal neuralgia treatment market is expected to hold a significant position due to increasing awareness among people about the condition. The Facial Pain Research Foundation and Intl Trigeminal Neuralgia and Me organized the International Trigeminal Neuralgia Awareness Day on October 7th every year. The market in Asia Pacific region is expected to grow at lucrative rate, owing to large number of population. According to a study published by Omics International, in China an estimated 4,458,090 people that is 2.6% among the total population are suffering from this condition. Market in emerging economies offer opportunities to market players in trigeminal neuralgia treatment market.

Click To Reading More On Trigeminal Neuralgia Treatment Market

About Coherent Market Insights:

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at

[email protected]

https://www.coherentmarketinsights.com/phase-xs/

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]